Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices.

Authors

Shruti Rao
Beth Pitel
Alex H Wagner
Simina M Boca
Matthew McCoy
Ian King
Samir Gupta
Ben Ho Park
Jeremy L Warner
James Chen
Peter Rogan, The University of Western OntarioFollow
Debyani Chakravarty
Malachi Griffith
Obi L Griffith
Subha Madhavan

Document Type

Article

Publication Date

7-1-2020

Journal

JCO Clin Cancer Inform

Volume

4

First Page

602

Last Page

613

URL with Digital Object Identifier

10.1200/CCI.19.00169

Abstract

PURPOSE: The cancer research community is constantly evolving to better understand tumor biology, disease etiology, risk stratification, and pathways to novel treatments. Yet the clinical cancer genomics field has been hindered by redundant efforts to meaningfully collect and interpret disparate data types from multiple high-throughput modalities and integrate into clinical care processes. Bespoke data models, knowledgebases, and one-off customized resources for data analysis often lack adequate governance and quality control needed for these resources to be clinical grade. Many informatics efforts focused on genomic interpretation resources for neoplasms are underway to support data collection, deposition, curation, harmonization, integration, and analytics to support case review and treatment planning.

METHODS: In this review, we evaluate and summarize the landscape of available tools, resources, and evidence used in the evaluation of somatic and germline tumor variants within the context of molecular tumor boards.

RESULTS: Molecular tumor boards (MTBs) are collaborative efforts of multidisciplinary cancer experts equipped with genomic interpretation resources to aid in the delivery of accurate and timely clinical interpretations of complex genomic results for each patient, within an institution or hospital network. Virtual MTBs (VMTBs) provide an online forum for collaborative governance, provenance, and information sharing between experts outside a given hospital network with the potential to enhance MTB discussions. Knowledge sharing in VMTBs and communication with guideline-developing organizations can lead to progress evidenced by data harmonization across resources, crowd-sourced and expert-curated genomic assertions, and a more informed and explainable usage of artificial intelligence.

CONCLUSION: Advances in cancer genomics interpretation aid in better patient and disease classification, more streamlined identification of relevant literature, and a more thorough review of available treatments and predicted patient outcomes.

Notes

https://pubmed.ncbi.nlm.nih.gov/32644817/

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.